Company Description
GeneDx Holdings Corp., a genomics company, provides personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery.
The company accelerate the use of genomics and leverage clinical data to enable precision medicine as the standard of care.
It utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patients.
The company offers genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening.
GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
| Country | United States |
| Founded | 2017 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 1,000 |
| CEO | Katherine Stueland |
Contact Details
Address: North Tower, 6th Floor Stamford, Connecticut 06902 United States | |
| Phone | 888 729 1206 |
| Website | genedx.com |
Stock Details
| Ticker Symbol | WGS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818331 |
| CUSIP Number | 81663L200 |
| ISIN Number | US81663L2007 |
| Employer ID | 85-1966622 |
| SIC Code | 8000 |
Key Executives
| Name | Position |
|---|---|
| Katherine A. Stueland | President, Chief Executive Officer and Director |
| Kevin Feeley CPA | Chief Financial Officer |
| Dr. Bryan M. Dechairo Ph.D. | Chief Operating Officer |
| Eric Olivares Ph.D. | Chief Product and Technology Officer |
| Heidi C. Chen J.D. | Chief Legal Officer |
| Jami Biliboaca | Head of People Strategy |
| Paul Kruszka FACMG, M.D., M.P.H. | Chief Medical Officer |
| Melanie Duquette | Chief Growth Officer |
| Sabrina Dunbar | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2025 | SCHEDULE 13D/A | Filing |
| Feb 20, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 20, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 20, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 20, 2025 | 10-K | Annual Report |
| Feb 18, 2025 | SCHEDULE 13D/A | Filing |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Feb 5, 2025 | SCHEDULE 13G | Filing |